Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-20-000551.pdf
0001558370-20-000551.rtf
0001558370-20-000551.xls
EX-101.SCH - EX-101.SCH
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000834237-20-004751.pdf
0000834237-20-004751.rtf
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000902219-20-000303.pdf
0000902219-20-000303.rtf
0000902219-20-000303.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-20-006333.pdf
0001104659-20-006333.rtf
0001104659-20-006333.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

 View HTML
0001047469-20-000448.pdf
0001047469-20-000448.rtf
0001047469-20-000448.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-20-005550.pdf
0001104659-20-005550.rtf
0001104659-20-005550.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

 View HTML
0001047469-20-000348.pdf
0001047469-20-000348.rtf
0001047469-20-000348.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-000551.pdf
0001179110-20-000551.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-000552.pdf
0001179110-20-000552.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-20-000136.pdf
0001558370-20-000136.rtf
0001558370-20-000136.xls
EX-101.SCH - EX-101.SCH